Nuvectis's NXP800 Granted FDA Orphan Drug Designation For ARID1a-Deficient Ovarian Cancers

On Thursday, Nuvectis Pharma, Inc. (NVCT) announced that the FDA has awarded Orphan Drug Designation to NXP800, designed for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.Orphan Drug Designation is given to drugs or biologics aimed at treating rare diseases or conditions.NXP800 is identified as an oral, small molecule that may serve as a novel GCN2 kinase activator.The company plans to provide an update on the study’s data in the fall of 2024.The material has been provided by InstaForex Company – www.instaforex.com

Author
Recent Posts

Insta Forex

Nuvectis’s NXP800 Granted FDA Orphan Drug Designation For ARID1a-Deficient Ovarian Cancers

Scilex Announces FDA Approval Of SNDA For Label Updates To Gloperba

Recommended

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX

Shareholders that lost money on Extreme Networks, Inc. (EXTR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

Shareholders of Outset Medical, Inc. Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – OM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 7, 2024 in Lululemon Athletica Inc. Lawsuit – LULU

Shortcodes Ultimate

Welcome Back!

Retrieve your password